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Abstract
Background One of the most important complications of the one anastomosis gastric bypass (OAGB) is enterobilio acid reflux
(EBAR).We report the concept of the long pouch Roux-en-Y gastric bypass (LPRYGB)meaning a Roux-en-Ywith a long pouch
and a 100-cm alimentary limb to avoid EBAR, with a long biliopancreatic limb to increase metabolic effects.
Methods A total of 300 LPRYGB cases in a 4-year period, with a 90% follow-up rate, were analysed. Anthropometric, technical
feasibility, morbidity, weight loss and comorbidity outcomes were analysed.
Results The percentage total weight loss (%TWL) was 30.5% at 4 years of follow-up (32.3% in primary and 28.3% in revisions).
Six intra-operative (2%) and 28 postoperative complications (9.3%) were seen. Out of this 28 complications, 11 (3.6%) were late
complications. Reoperations were performed in 15 patients (5.0%). Clinically relevant EBAR was present in 3 cases only (1%)
4 years after the operation.
Conclusions The LPRYGB combines the main advantages of the OAGB (light restriction and moderate malabsorption) with the
anti-reflux effect from the Roux-en-Y diversion.
Keywords Long pouch gastric bypass . LPGB .Morbid obesity . Biliary reflux . Hypoglycaemia . Roux-en-Y diversion . Entero
bilioacid reflux . EBAR
Background
In Roux-en-Y gastric bypass (RYGB), intermediate and long-
term weight regain raises some concerns. Christou et al. [1]
demonstrated both morbidly obese (20.4%) and superobese
(34.9%) patients with RYGB experienced significant weight
regain from the nadir to 5 years and again from 5 to 10 years.
Other authors have better durability of weight loss. Adams [2]
reported a 26.9% total weight loss (TWL) and a 51%
remission rate of type 2 diabetes (T2DM) 12 years after sur-
gery. According to the SOS Study, recurrence of T2DM oc-
curs also in 50% of the initial successful remission cases
10 years after RYGB [3]. Hyperinsulinemic hypoglycaemia
is also a disturbing consequence in up to 8% of the patients
[4].
The one anastomosis gastric bypass (OAGB) is growing
fast in popularity as a simple, safe and effective procedure
compared with (RYGB) [5]. It seems to have better results
in terms of weight loss and diabetes control in the long run [6].
In 2010, we began to performOAGB andwe experienced a
reduction in the early and late morbidity, number of weight
regain cases and absence of hyperinsulinemic hypoglycaemic
episodes.
There is controversy about the incidence of “biliary reflux”,
after OAGB [7]. Different publications report enterobilio acid
reflux (EBAR) in low rates (2–4%) [8–10] But, in case of
revision procedures, rates are higher, mainly in failed band
revisions [11, 12].
In our first 200 OAGB cases, 44% of them for failed band
or sleeve, the most significant complication we had to face
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was EBAR (4%), which we decided to revise. Technically, we
performed a Roux-en-Y diversion with the “double loop tech-
nique” [13] cutting the afferent loop before the gastro-
ileostomy and creating a new side-to-side enteroenterostomy
100 cm far from the GE in the previous efferent limb achiev-
ing the same low-weight and good comorbidities control.
Subsequently, we decided to add this step in secondary
OAGB operations to prevent future reflux mainly in patients
with previous band, sleeve with GERD. We performed this as
a primary operation in patients with hiatus hernia larger than
3 cm or with symptomatic GERD. We call this variation
“Long Pouch Roux-en Y Gastric Bypass” (LPRYGB). The
main differences between the three bypass versions are shown
in Fig. 1.
Important differences compared with regular RYGB are
longer gastric pouch (> 16 cm), larger anastomosis (3 cm)
and a longer biliopancreatic limb (200 cm). Comparing with
RYGB, these patients clearly have less restriction (large anas-
tomosis) and some steatorrhea because of fat hypo-absorption.
Here we report the outcomes of our LPRYGB cases with
4 years of follow-up.
Methods
We retrospectively analysed our prospectively collected data
on 389 LPRYGB cases performed from 2013 until August
2018. Average follow-up time was 24.4 months and 61 pa-
tients with less than 6 months follow-up were excluded; 28
patients (7.2%) were lost for follow-up; in the remaining
cases, missing data were completed by case note reviews
and phone calls.
Every patient was fully informed about the clinical profile,
expected outcomes and risks of this procedure and signed a
specific informed consent. The institutional “review board”
approved the study, verified the compliance with ethical stan-
dards. Basic descriptive statistics were used.
Preoperative Course
All patients had a multidisciplinary approach following the
national Portuguese guidelines [14, 15] to the preoperative
and postoperative period. An endocrinologist, psychologist,
nutritionist, psychiatrist, the anaesthesiologist and the surgeon
made the preoperative assessment. All the patients were sub-
mitted to a regular evaluation with complementary diagnostic
tests including an endoscopy with oesophageal mucosa biop-
sy whenever an esophagitis was diagnosed. The revision cases
had also a radiologic assessment with upper gastrointestinal
series or CT scan. Gastro-oesophageal reflux (GERD) was
considered to be present based on the symptoms, endoscopic,
pathologic or radiologic findings.
All patients had low calorie preoperative regimen
(1000 Kcal/day) for a minimum of 7 days.
Surgical Technique
Figure 1 shows a comparison between RYGB, OAGB and
LPRYGB. Important remarks based on already described
LPGB technique [16] are as follows:
– Angle of His is dissected and hiatal hernias bigger than
3 cm are repaired usually with a posterior cruroplasty.
“Incisura angularis” dissection is performed at the level
or below the “crows foot”. A long and slim gastric pouch
is constructed with endostaplers over a 36 French bougie.
– Like in OAGB, we select a first spot 200 cm from the
Treitz angle for the gastroenterostomy defining the length
of the future biliopancreatic limb. This length is tailored
accordingly to the patient characteristics. In superobese or
diabetic people, we increase it by 50 cm (250 cm). In
older people (above 60 years), BMI under 40 Kg/m2 or
vegetarians, we reduce it by 50 cm (150 cm).
– Then, we measure 1 m of bowel distally to be the alimen-
tary limb, defining a spot, plus more 3 m for the common





Fig. 1 Technique comparison
between a Roux-en-Y gastric by-
pass (RYGB), b one anastomosis
(OAGB) and c long pouch Roux-
en-Y gastric bypass (LPRYGB)
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bowel), we reduce the length of the BP limb in order to
achieve those lengths.
– We strive to measure the entire bowel but, in case of a
short mesentery or heavy bowel, as soon as we are able to
get the referred measurements (1 + 3 m) we stop to count
further to avoid iatrogenic injury.
– After those measurements, at the first spot, a
gastroenterostomy (GE) is made on the anterior surface
of the gastric pouch, with a white 30-mm stapler maga-
zine. The enterotomy is closed with Vicryl 2/0, continu-
ous suture.
– A side to side entero-enterostomy (EE) with a 60-mm
white stapler cartridge is performed between a second
spot 1 m distal to the GE and the BP limb immediately
before the GE, defining the alimentary limb length (1 m).
– After a methylene blue test to the GE, dividing the bowel
between the two anastomosis with a 60-mm white car-
tridge does maturation of the Roux-en-Y diversion.
– The intermesenteric and the Petersen space are closed
with a purse string 2/0 silk. Application of a spray of
fibrin glue on the staple lines and anastomosis is usually
done. The drainage of the abdominal cavity is selectively
used. Nasogastric tubes or urinary catheters are not used
routinely. The port sites with a diameter bigger than
10 mm are closed with transparietal non-resorbable
stitches.
Postoperative Course
Patients are mobilized at 6 h, allowed liquids 12 h postopera-
tively and discharged on the second postoperative day.
Enoxaparin is prescribed (40 to 100 mg a day) for 7 days,
ursodeoxycholic acid (250mg 2 or 3 times a day) for 3 months
and pantoprazole (40 mg a day) for 6 months. This extended
use of proton pump inhibitors is due to the longer pouch than
that used in the LPRYGB. In a recent study by Edholm et al.
[17] it was shown that the relative risk of marginal ulcer for-
mation increased with 14% with each centimetre of stapler
used for the pouch. The protocol includes supplementation
with multivitamins (Fitforme® or Bariatric Inspire®) plus
high-dose cholecalciferol pills (22,400 UI each 2 weeks).
The protocol includes observations every 3 months
during the first year, every 6 months in the second
and then, once a year. Laboratorial evaluation is done
at 1, 6 and 12 months in the first year and then once a
year. Once a year, we check for the Helicobacter pylori
presence (and eradication if positive in the urea breath
test) and ask for an abdominal ultrasound test to detect
biliary stones and steatosis evolution. In order to eval-
uate possible esophagitis, gastritis or marginal ulcer, a
barium swallow and an upper GI endoscopy are request-
ed at the end of the first postoperative year. Further
endoscopic evaluations are asked after 2 and 5 years
or whenever the patient complains are suggestive of
reflux, obstructive or ulcerative disease.
Definitions for Remission of Comorbidities
T2DM Remission of T2DM was defined as a HbA1C level <
6%. Amelioration was patient was able to reduce the antidia-
betic medications or able to get off some of the antidiabetics
(e.g. insulin).
Hypertension Amelioration is reduction in dosage of antihy-
pertensive medication or stopping of some of the medications.
Cure was defined when all antihypertensive medications were
stopped.
Dyslipidaemia Amelioration is reduction in dosage of lipid-
lowering medication or stopping of some of the medications
or improved blood levels of either HDL cholesterol (increase)
or a decrease of LDL cholesterol. Cure was defined when all
lipid-lowering medication were stopped.
Osteoarthritis/Degenerative Joint Disease Amelioration is a
reduction of complaints or reduction of medication.
Obstructive Sleep Apnoea (OSA) Amelioration is defined as a
lowering of the Apnoea–Hypopnoea Index (AHI) or reduction
of symptoms. Cure was defined as cessation of C-PAP.
Gastro-Esophageal Reflux Disease (GERD) Amelioration is de-
fined as reduction of symptoms or cessation/reduction of med-
ication (like proton-pomp inhibitors (PPIs)).
Results
We analysed the outcomes of 300 operated cases of LPRYGB,
169 primary and 131 revision cases. The recorded periopera-
tive data are presented in Table 1.
Table 1 Perioperative institutional data (basic demographics)
Variable LPRYGB
Women (n) 243 (81%)
Age (years) 45.8 (16–70)
BMI (Kg/m2) 41.3 (27,8-56,9)
Mean operative time (min) 65 (45–195)
Conversion rate 0
Average hospital stay (days) 3.2 (1–23)
Early readmission rate 10 (3.3%)
Late readmission rate 8 (2.7%)
Mean Follow-up (months) 24.4 (6–48)
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In order to get a 3-m common limb, intra-operatively, we
had to shorten the BP limb four times. The average BP limb in
all the 300 cases was 217.6 cm.
The total morbidity rate was 9.3% (5.6% early and 3.6%
late events). The total morbidity in primary cases was 8.9% in
revisions was 9.6% (Table 2).
Out of 17 (5.6%) cases of early complications, 10 (3.3%)
were Clavien Dindo grade IIIb (with reoperations), 5 after
primary and 5 after revision cases. The other 7 cases were
grade I or II. No grade IV (life-threatening complications)
occurred.
The weight evolution of the 300 cases was from 111.2 Kg
(BMI 41.3 Kg/m2) in the preoperative time to 76.9 Kg (BMI
29.6 Kg/m2) 48 months after the surgery. The percentage total
weight loss (%TWL) was 30.5% at 4 years of follow-up
(Fig. 2), 32.3% in primary cases and 28.3% in revision ones.
For the revisional cases, the weight before the revision oper-
ation was used for calculation of TWL.
The re-operative rate was 5.0% (2.7% in primary and 2.3%
in revisions) (Table 2).
Marginal ulcers were diagnosed in 3 patients. One (pene-
tration to abdominal anterior wall) needed reoperation
(gastroileostomy reconstruction). The remaining 2 cases were
successfully dealt with medical management. One revision
patient presented 3 months after the operation with steator-
rhoea, anaemia and hypoproteinemia. He was managed with
protein intake reinforcement plus pancreatic enzyme and
probiotics with good result.
EBAR was seen in 3 patients (1.0%), two of them
successfully treated with surgery. Both were submitted
to recurrent hiatus hernia repair (posterior cruroplasty),
one with mesh repair, and the other with a Toupet-like
fundoplication with the gastric remnant. One case is under
medical treatment with satisfactory result. No “de novo”
cases were found.
Th e r e w e r e n o c a s e s o f h y p e r i n s u l i n em i c
hypoglycaemia or significant anaemia. We performed 2
cholecystectomies in cases of symptomatic gallstone dis-
ease. Mortality was 0%.
Table 2 Overview of the early and late postoperative complications after long pouch Roux-en-Y gastric bypass (LPRYGB)
Postoperative complications
EARLY
Global (n = 300) Primary (n = 169) Revisional (n = 131)
n Reops n Reops n Reops
Hemoperitoneum 2 2 2 2 – –
Intra-abdominal infection 2 2 1 1 1 1
Pouch leak (His angle) 1 1 – – 1 1
Ileo-ileal anastomosis leak 1 1 – – 1 1
Bowel perforation 1 1 1 1 – –
Wound infection 3 – 2 – 1 –
Abdominal wall hematoma 2 1 1 1 1 –
Port site hernia 3 2 1 – 2 2
Haematochezia 1 – 1 – – –
Pleural effusion 1 – 1 – – –









Global (n = 300) Primary (n = 169) Revisional (n = 131)
n Reops n Reops n Reops
Alimentary intolerance 3 2 1 – 2 2
EBAR 3 2 2 2 1 –
Marginal ulcer 3 1 2 1 1 –
Steatorrhea 1 – – – 1 –

























Clavien-Dindo: Grade I: 3 cases; Grade II: 4 cases; Grade III: 10 cases; Grade IV: 0; Grade V: 0
;EBAR, entero bilioacid reflux; Reops, reoperations
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The main nutritional deficiencies were iron (13.7%),
Vitamin D 25OH (11.7%), folate (3.0%) and Vitamin B12
(2.7%). Hair loss was seen in 8.0% of the cases and chronic
diarrhoea in 1.3%. Hypoproteinemia was present in only 3.3%
of the cohort.
The comorbidity improvement was in line with the OAGB,
improvement in 82.2% of the type 2 diabetic patients and 70%
of the ones with high blood pressure (Table 3).
Table 4 gives the indications for revisional surgery af-
ter either gastric band or sleeve gastrectomy. The majority
of the failed gastric bands or sleeve gastrectomies were
because of weight regain. In case of GERD, the symptoms
were confirmed by esophagogastroduodenoscopy and
hence, revision was offered.
Discussion
The surgeons performing OAGB are claiming better out-
comes and fewer complications compared with RYGB [7,
18–21]. Biliary reflux or EBAR is a debated topic, even if
the incidence reported is low [6, 11, 12, 22]. This is because
most of the cases are refractory to medical treatment [23, 24]
and some patients, facing the disturbing clinical complaints,
may require surgical treatment. In our initial practice with
OAGB, we had 4% of EBAR after 200 and 2.6% after 650
cases [25]. By adding a Roux-en-Y diversion to those primary
OAGB, the EBAR incidence decreased to 1% [25].
There is still a lot of discussion about the relation between
biliary reflux after OAGB and risk of gastric stump cancer
[26]. EBAR carrying bile into the stomach is a common find-
ing in upper GI endoscopies, and many authors discuss the
generally accepted relation between bile presence and gastric
cancer [27, 28]. The presence of bile in the oesophagus is
clearly related with the occurrence of Barrett’s epithelium.
The presence of duodenal enzymes leads to oesophageal epi-
thelial destruction in animal [14] and humans [15] and pro-
motes the risk for cancer.
The technique we are proposing here avoids biliary reflux
and gastric mucosa and oesophagus bile wash, so the tech-
nique avoids these potential risks to patients.
But EBAR may be a late complication even after RYGB
[16]. The reason for this may be the anatomical or functional
shortness of the alimentary limb. A similar process may occur
in LPRYGB. When we revised three cases of oesophageal
reflux with EBAR, two of them presented short alimentary
limbs (50 and 60 cm), probably from wrong measurements,
which we elongated. Since then, after 50 cases, we increased
the alimentary limb up to 100 cm. All 3 cases with EBAR had
previous hiatal hernias (one of them big) and in the 2
Fig. 2 Percentage total weight loss (%TWL) in both primary and revision
procedures plus follow-up rates at each time point. The blue line shows
the total rates of the procedure. The green line shows the rates of primary
long pouch Roux-en-Y gastric bypass (LPRYGB). The red line shows the
rates of revisional long pouch Roux-en-Y gastric bypass (LPRYGB). The
asterisk indicates that for revision procedures, the weight before the revi-
sion operation was used for calculation of TWL
Table 4 Indications for revisional surgery (N)
Band (n) Sleeve (n) Total (N)
Weight regain 80 14 94
GERD 3 4 7
GERD + weight regain 21 9 30
Total (N) 104 27 131
GERD gastro-oesophageal reflux disease
Table 3 Comorbidities and amelioration rates
Comorbidity Preoperative status % amelioration % off treatments
T2DM 84 (28%) 80.2% 54%
Hypertension 139 (46.3%) 70% 44%
Dyslipidaemia 124 (41.3%) 54% 42%
OSA 81 (27%) 67% 63%*
Degenerative joint disease 126 (42%) 55% 49%
GERD 141 (47.7%) 91% 86%
*off CPAP
T2DM type 2 diabetes mellitus, OSA obstructive sleep apnoea, GERD gastro-oesophageal reflux disease
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reoperated cases, both hernias were recurrent and treated again
with good symptomatic control.
Björklund concluded that the gastric pouch and the Roux
limb behave as a common cavity during food ingestion and
have the same intraluminal pressure [25]. The pressure does
not correlate to weight loss nor to the meal size or rate of
eating. Also, it is not clear if this status lasts out of the alimen-
tary bolus passage time. But if this shared pressure stands, the
EBAR fluid may progress backwards from the entero-
enterostomy up to the lower oesophageal sphincter [18] and
may induce oesophageal mucosa inflammation or even
erosion.
In consequence, each surgeon must keep these issues in
mind and try to detect and treat the EBAR conservatively
(alimentary behaviour change, cholestyramine and
prokinetics). If he does not succeed, check for any anatomical
hiatal defect and propose the patient a surgical repair.
Alimentary limb elongation, cruroplasty, Hill-type
gastropexy, or partial fundoplication using the gastric remnant
or even a Belsey-Mark IV procedure are possible solutions
[19]. Endoscopic procedures and techniques (Stretta®,
LINX®) may become valuable in the near future, as new
devices are now available with interesting outcomes [20, 21,
29].
Another important issue is the gastric pouch length and
width. It is consensual that the pouch must be long and
slim to avoid future dilation and bile reflux [11]. If a very
narrow tube is more prone to anatomic or functional ste-
nosis (torsion or dysmotility), larger pouches may lead to
excessive acid production and pure acid GERD [30]. Our
suggestion is to perform a long pouch calibrated on 36
French bougie avoiding any rotational mechanism or
stricture.
In another view, if a long and slim pouch helps to avoid
oesophageal mucosa EBAR exposition, a longer pouch may
also inducemore acidity that, at least theoretically, may lead to
an increased risk of marginal ulcer. By now, in our data, we
have not seen such an effect but we need to check in future re-
evaluations of this cohort and longer follow-up data will pro-
vide these details.
Ideally, the bowel length must always be measured. There
is now enough evidence showing that a long BP limb provides
more weight loss and better metabolic effect [31–36]. In
LPRYGB, the common channel is usually 200 cm and the
alimentary limb 100 cm. The common channel length must
be about 300 cm or more to avoid malnutrition. When mea-
suring the bowel, if 300 cm are not affordable for the common
channel, we reduce the BP limb length as much as necessary
to get at least this common channel safe length.
Our experience shows that LPRYGB is a good strategic
option for patients exposed to EBAR presence or potential
risk and seems to be an effective and safe approach in primary
and revision cases. It allows very safe surgery, excellent
weight loss and comorbidity control, even though we need
longer follow-up and further prospective comparative studies
to certify these apparent advantages.
Conclusion
The LPRYGB combines the main advantages of the OAGB
(reduced restriction and moderate fat malabsorption) with the
anti-reflux effect of the Roux-en-Y diversion. It is a safe and
technically reproducible procedure. The weight loss and the
comorbidity control at 48 months are comparable to literature
OAGB published data.
Our outcomes confirm a low rate of enterobilio acid reflux
as RYGB. It is also much convenient and effective as a sal-
vage technique in cases of failed restrictive surgery, usually
weight regain, reflux or both together.
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